Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SGMT

Sagimet Biosciences Inc

May 09 • 04:00PM ET

4.57

Dollar change +0.13
Percentage change 2.93	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO IWO IWC VTWG VTWV BTEC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.28	Insider Own	46.04%	Shs Outstand	21.38M	Perf Week	2.70%
Market Cap	145.87M	Forward P/E	-	EPS next Y	-3.73	Insider Trans	0.10%	Shs Float	17.22M	Perf Month	-9.68%
Income	-27.88M	PEG	-	EPS next Q	-0.39	Inst Own	38.06%	Short Float	12.79%	Perf Quarter	-23.83%
Sales	2.00M	P/S	72.94	EPS this Y	22.74%	Inst Trans	-	Short Ratio	2.68	Perf Half Y	24.18%
Book/sh	3.98	P/B	1.15	EPS next Y	-81.70%	ROA	-	Short Interest	2.20M	Perf Year	-
Cash/sh	2.97	P/C	1.54	EPS next 5Y	-	ROE	-	52W Range	2.13 - 20.71	Perf YTD	-15.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.23%	ROI	-30.61%	52W High	-77.93%	Beta	-
Dividend TTM	-	Quick Ratio	17.04	Sales past 5Y	0.00%	Gross Margin	94.85%	52W Low	114.55%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	17.04	EPS Y/Y TTM	-	Oper. Margin	-1537.00%	RSI (14)	50.73	Volatility	8.67% 7.84%
Employees	10	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-1393.80%	Recom	1.00	Target Price	40.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	12.87%	Payout	-	Rel Volume	0.47	Prev Close	4.44
Sales Surprise	-	EPS Surprise	33.63%	Sales Q/Q	-	Earnings	Mar 25 BMO	Avg Volume	821.12K	Price	4.57
SMA20	7.08%	SMA50	-6.65%	SMA200	-38.40%	Trades		Volume	396,172	Change	2.93%

Date	Action	Analyst	Rating Change	Price Target Change
May-02-24	Initiated	H.C. Wainwright	Buy	$32
Mar-25-24	Initiated	Leerink Partners	Outperform	$26
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight	$67
Aug-08-23	Initiated	JMP Securities	Mkt Outperform	$30
Aug-08-23	Initiated	Goldman	Buy	$33

May-07-24 08:00AM	Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 (GlobeNewswire)
May-06-24 08:00AM	Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer (GlobeNewswire)
Apr-22-24 08:00AM	Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 (GlobeNewswire)
Mar-27-24 04:01PM	Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat (GlobeNewswire) +9.56%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) +15.74%
06:15AM	Loading…
06:15AM	Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Feb-29-24 08:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Jan-25-24 08:58PM	Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock (GlobeNewswire) -13.62%
Jan-23-24 05:45PM	Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock (GlobeNewswire)
Jan-22-24 11:10PM	Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH (PR Newswire) +170.09%
07:00AM	Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH (GlobeNewswire)
Dec-04-23 08:00AM	Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic (GlobeNewswire) +7.12%
Nov-28-23 08:00AM	Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit (GlobeNewswire)
Nov-22-23 08:00AM	Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +13.58%
Nov-13-23 08:00AM	Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -13.73%
08:30AM	Loading…
Nov-10-23 08:30AM	Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023 (GlobeNewswire) -7.68%
Oct-24-23 11:00AM	Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting 2023 (GlobeNewswire)
Oct-18-23 04:05PM	Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference (GlobeNewswire)
Sep-27-23 04:05PM	Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma (GlobeNewswire)
Aug-29-23 10:21AM	Load Up, Says Goldman Sachs About These 2 Strong Buy Stocks (TipRanks)
Aug-21-23 04:02PM	Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-15-23 04:04PM	Sagimet Biosciences Announces Closing of Underwriters Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering (GlobeNewswire)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Jul-20-23 04:05PM	Sagimet Biosciences Announces Leadership Changes (GlobeNewswire)
Jul-13-23 09:10PM	Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Happel David	President & CEO	Mar 26 '24	Buy	5.27	12,100	63,731	639,200	Mar 28 04:08 PM
Happel David	President & CEO	Dec 07 '23	Buy	4.10	1,600	6,560	627,100	Dec 08 04:05 PM
Happel David	President & CEO	Nov 16 '23	Buy	2.35	590	1,386	590	Nov 20 09:59 PM
Kemble George	Executive Chairman	Sep 07 '23	Option Exercise	0.79	5,630	4,448	5,630	Sep 08 04:15 PM
SEIDENBERG BETH C	Director	Jul 18 '23	Buy	16.00	46,875	750,000	46,875	Jul 20 04:20 PM
NEW ENTERPRISE ASSOCIATES 13 L	10% Owner	Jul 18 '23	Buy	16.00	30,000	480,000	3,850,275	Jul 20 06:56 PM
NEW ENTERPRISE ASSOCIATES 13 L	10% Owner	Jul 18 '23	Sale	16.00	662	10,592	3,820,275	Jul 20 06:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGMT

Sagimet Biosciences Inc

Upgrade your FINVIZ experience